Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Return on Equity: 2010-2025

Historic Return on Equity for China Pharma Holdings (CPHI) over the last 15 years, with Sep 2025 value amounting to -0.43%.

  • China Pharma Holdings' Return on Equity rose 25.00% to -0.43% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.43%, marking a year-over-year increase of 25.00%. This contributed to the annual value of -0.62% for FY2024, which is 10.00% down from last year.
  • Per China Pharma Holdings' latest filing, its Return on Equity stood at -0.43% for Q3 2025, which was up 20.69% from -0.54% recorded in Q2 2025.
  • China Pharma Holdings' Return on Equity's 5-year high stood at -0.39% during Q1 2021, with a 5-year trough of -1.12% in Q4 2022.
  • For the 3-year period, China Pharma Holdings' Return on Equity averaged around -0.59%, with its median value being -0.59% (2023).
  • In the last 5 years, China Pharma Holdings' Return on Equity surged by 199bps in 2021 and then tumbled by 59bps in 2022.
  • Over the past 5 years, China Pharma Holdings' Return on Equity (Quarterly) stood at -0.53% in 2021, then crashed by 59bps to -1.12% in 2022, then surged by 66bps to -0.45% in 2023, then declined by 21bps to -0.66% in 2024, then grew by 25bps to -0.43% in 2025.
  • Its Return on Equity was -0.43% in Q3 2025, compared to -0.54% in Q2 2025 and -0.62% in Q1 2025.